Business Wire

Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results

Del

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2017. Total revenues for the fourth quarter of 2017 were $5.9 billion compared to $7.3 billion for the same period in 2016. Net loss for the fourth quarter of 2017 was $3.9 billion, or $2.96 loss per share, compared to net income of $3.1 billion, or $2.34 per diluted share for the same period in 2016. The net loss for the fourth quarter includes an estimated $5.5 billion charge related to the enactment of the Tax Cuts and Jobs Act (Tax Reform)(1). Non-GAAP net income for the fourth quarter of 2017 was $2.3 billion, or $1.78 per diluted share, compared to $3.6 billion, or $2.70 per diluted share for the same period in 2016. Non-GAAP net income excludes amounts related to acquisition-related, up-front collaboration, stock-based compensation and other expenses, and the impact of Tax Reform.

Full year 2017 total revenues were $26.1 billion, compared to $30.4 billion for 2016. Net income for 2017 was $4.6 billion, or $3.51 per diluted share, compared to $13.5 billion, or $9.94 per diluted share for 2016. Non-GAAP net income for 2017 was $11.7 billion, or $8.84 per diluted share, compared to $15.7 billion, or $11.57 per diluted share for 2016.

  Three Months Ended   Twelve Months Ended
December 31, December 31,
(In millions, except per share amounts) 2017   2016 2017   2016
Product sales $ 5,837 $ 7,216 $ 25,662 $ 29,953
Royalty, contract and other revenues 112   104   445   437
Total revenues $ 5,949   $ 7,320   $ 26,107   $ 30,390
 
Net income (loss) attributable to Gilead $ (3,865 ) $ 3,108 $ 4,628 $ 13,501
Non-GAAP net income* $ 2,343 $ 3,585 $ 11,654 $ 15,713
 
Diluted earnings / (loss) per share** $ (2.96 ) $ 2.34 $ 3.51 $ 9.94
Non-GAAP diluted earnings per share* $ 1.78 $ 2.70 $ 8.84 $ 11.57
*  

Non-GAAP net income and non-GAAP diluted earnings per share exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses, and the impact of Tax Reform. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 8, 9 and 10.

 
**

Shares used in loss per share calculation for the three months ended December 31, 2017 exclude 13 million shares from dilutive equity awards.

___________________________________

(1) Refer to page 3 for details.

Product Sales

Total product sales for the fourth quarter of 2017 were $5.8 billion, compared to $7.2 billion for the same period in 2016. Product sales for the fourth quarter of 2017 were $4.1 billion in the United States, $1.1 billion in Europe and $553 million in other locations. Product sales for the fourth quarter of 2016 were $4.9 billion in the United States, $1.4 billion in Europe and $870 million in other locations.

Total product sales during 2017 were $25.7 billion, compared to $30.0 billion in 2016. For 2017, product sales were $18.1 billion in the United States, $5.0 billion in Europe and $2.6 billion in other locations. For 2016, product sales were $19.3 billion in the United States, $6.1 billion in Europe and $4.6 billion in other locations.

Antiviral Product Sales

Antiviral product sales, which include sales of our HIV, chronic hepatitis B (HBV) and chronic hepatitis C (HCV) products, were $5.2 billion for the fourth quarter of 2017 compared to $6.6 billion for the same period in 2016. For 2017, antiviral product sales were $23.3 billion compared to $27.7 billion in 2016.

  • HIV and HBV product sales for the fourth quarter of 2017 were $3.7 billion compared to $3.4 billion for the same period in 2016 and $14.2 billion for the full year 2017 compared to $12.9 billion in 2016. The increases were primarily driven by the continued uptake of our tenofovir alafenamide (TAF)-based products, Genvoya® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg), Descovy® (emtricitabine 200 mg/tenofovir alafenamide 25 mg) and Odefsey® (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg).
  • HCV product sales, which consist of Harvoni® (ledipasvir 90 mg/sofosbuvir 400 mg), Sovaldi® (sofosbuvir 400 mg), Epclusa® (sofosbuvir 400 mg/velpatasvir 100 mg) and Vosevi® (sofosbuvir 400 mg/velpatasvir 100 mg/voxilaprevir 100 mg), were $1.5 billion for the fourth quarter of 2017 compared to $3.2 billion for the same period in 2016 and $9.1 billion for the full year 2017 compared to $14.8 billion in 2016. The declines were across all major markets.

Other Product Sales

Other product sales, which include Letairis® (ambrisentan), Ranexa® (ranolazine) and AmBisome® (amphotericin B for liposome injection), were $624 million for the fourth quarter of 2017 compared to $621 million for the same period in 2016. For 2017, other product sales were $2.3 billion compared to $2.2 billion in 2016.

Operating Expenses

  Three Months Ended   Twelve Months Ended
December 31, December 31,
(In millions) 2017   2016 2017   2016
Research and development (R&D) expenses $ 1,150 $ 1,208 $ 3,734 $ 5,098
Non-GAAP R&D expenses* $ 845 $ 959 $ 3,291 $ 3,749
 
Selling, general and administrative (SG&A) expenses $ 1,252 $ 992 $ 3,878 $ 3,398
Non-GAAP SG&A expenses* $ 923 $ 938 $ 3,363 $ 3,194
*  

Non-GAAP R&D and SG&A expenses exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 8, 9 and 10.

 

During the fourth quarter of 2017, compared to the same period in 2016:

  • R&D expenses decreased primarily due to the 2016 impacts of ongoing milestone payments and an impairment charge related to in-process R&D (IPR&D), partially offset by Gilead’s purchase of Cell Design Labs, Inc. (Cell Design Labs) in 2017.
  • Non-GAAP R&D expenses* decreased primarily due to the 2016 impact of ongoing milestone payments.
  • SG&A expenses increased primarily due to acquisition-related costs associated with Gilead’s acquisition of Kite Pharma, Inc. (Kite).

For 2017 compared to 2016:

  • R&D expenses decreased primarily due to the 2016 impacts of impairment charges related to IPR&D, ongoing milestone payments, up-front collaboration expenses related to Gilead’s license and collaboration agreement with Galapagos NV and Gilead’s purchase of Nimbus Apollo, Inc., partially offset by Gilead’s purchase of Cell Design Labs in 2017.
  • Non-GAAP R&D expenses* decreased primarily due to the 2016 impact of ongoing milestone payments.
  • SG&A expenses increased primarily due to acquisition-related costs associated with Gilead’s acquisition of Kite.
  • Non-GAAP SG&A expenses* increased primarily due to higher branded prescription drug fee expense.

Provision for Income Taxes and Tax Reform

Provision for income taxes was $6.0 billion for the fourth quarter of 2017 compared to $821 million for the same period in 2016 and $8.9 billion for the full year 2017 compared to $3.6 billion in 2016. The increases were primarily due to an estimated charge of $5.5 billion from Tax Reform, which was enacted on December 22, 2017 and lowers U.S. corporate income tax rates as of January 1, 2018, implements a territorial tax system and imposes a repatriation tax on deemed repatriated earnings of foreign subsidiaries. This estimate is provisional and based on our initial analysis and current interpretation. Given the complexity of the legislation, anticipated guidance from the U.S. Treasury, and the potential for additional guidance from the Securities and Exchange Commission (“SEC”) or the Financial Accounting Standards Board, this estimate may be adjusted during 2018.

Non-GAAP provision for income taxes excludes the estimated charge of $5.5 billion from Tax Reform. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 8, 9 and 10.

Cash, Cash Equivalents and Marketable Securities

As of December 31, 2017, Gilead had $36.7 billion of cash, cash equivalents and marketable securities compared to $32.4 billion as of December 31, 2016. During 2017, Gilead generated $11.9 billion in operating cash flow and in connection with the acquisition of Kite, Gilead issued $3.0 billion aggregate principal amount of senior unsecured notes and $6.0 billion aggregate principal amount of term loan facilities, of which $1.5 billion was repaid in December 2017. Additionally, Gilead paid cash dividends of $2.7 billion and utilized $954 million on stock repurchases.

Full Year 2018 Guidance

Gilead provided its full year 2018 guidance:

(In millions, except percentages and per share amounts)   Provided

February 6, 2018

Net Product Sales $20,000 - $21,000
Non-GAAP*
Product Gross Margin 85% - 87%
R&D Expenses $3,400 - $3,600
SG&A Expenses $3,400 - $3,600
Effective Tax Rate 21.0% - 23.0%
Diluted EPS Impact of Acquisition-related, Up-front Collaboration, Stock-Based Compensation and Other Expenses $1.41 - $1.51
*  

Non-GAAP Product Gross Margin, R&D and SG&A expenses and effective tax rate exclude acquisition-related, up-front collaboration, stock-based compensation and other expenses, and changes to our estimates relating to Tax Reform during 2018. A reconciliation between GAAP and non-GAAP full year 2018 guidance is provided in the tables on page 11.

 

Corporate Highlights

  • Announced that Executive Chairman John C. Martin, PhD will transition from his current role of Executive Chairman to Chairman of the Board of Directors effective March 9, 2018.
  • Announced the acquisition of Cell Design Labs, gaining new technology platforms that will enhance research and development efforts in cellular therapy.
  • Announced the launch of the Gilead COMPASS (COMmitment to Partnership in Addressing HIV/AIDS in Southern States) Initiative, a 10-year, $100 million commitment to support organizations working to address the HIV/AIDS epidemic in the Southern United States.
  • Announced the promotion of Alessandro Riva, MD, to Executive Vice President, Oncology Therapeutics, with responsibility for Gilead’s hematology and oncology programs, including cell therapy research and development.

Product & Pipeline Updates announced by Gilead during the Fourth Quarter of 2017 include:

HIV and Liver Diseases Programs

  • Presented data at The Liver Meeting® 2017 which included the announcement of:
    • Results from a Phase 2, randomized, placebo-controlled trial evaluating two doses of GS-0976, an oral, investigational inhibitor of Acetyl-CoA carboxylase, in patients with nonalcoholic steatohepatitis (NASH). The data demonstrate that the higher dose of GS-0976 (20 mg taken orally once daily) when administered for 12 weeks was associated with statistically significant reductions in hepatic steatosis (buildup of fat in the liver) and a noninvasive marker of fibrosis compared to placebo.
    • Results from an open-label Phase 2 study evaluating once-daily Harvoni for 12 weeks among HCV genotype 1 patients with severe renal impairment (creatinine clearance ≤ 30 mL/min). 100 percent of patients achieved a sustained virologic response 12 weeks after completing therapy (SVR12), including patients with compensated cirrhosis and those who had failed prior treatment.
    • Results from an open-label Phase 2 study evaluating once-daily Epclusa for 12 weeks among 79 liver transplant patients with genotype 1-4 chronic HCV infection. Treatment with Epclusa resulted in an overall SVR12 rate of 96 percent, including patients with cirrhosis and prior treatment failure, and was well tolerated.
    • Updated results from two Phase 3 studies demonstrating improved long-term bone and renal safety in HBV-infected patients 48-weeks after switching from Viread® (tenofovir disoproxil fumarate 300mg) to Vemlidy® (tenofovir alafenamide 25mg).
  • Announced detailed 48-week results from a Phase 3 study evaluating the efficacy and safety of switching virologically suppressed HIV-1 infected adult patients from a multi-tablet regimen containing a boosted protease inhibitor (bPI) to a fixed-dose combination of bictegravir (50 mg) (BIC), a novel investigational integrase strand transfer inhibitor, and emtricitabine/tenofovir alafenamide (200/25 mg) (FTC/TAF), a dual-NRTI backbone. In the ongoing study, BIC/FTC/TAF was found to be statistically non-inferior to regimens containing bPIs and demonstrated no treatment-emergent resistance at 48 weeks. The data were presented at IDWeek 2017.
  • Announced a new licensing agreement with the Medicines Patent Pool (MPP), a United Nations-backed public health organization, to expand access to BIC upon regulatory approval in the United States. Through this agreement, MPP can sub-license rights to BIC to generic drug companies in India, China and South Africa to manufacture therapies containing BIC for distribution in 116 low- and middle-income countries.

Oncology and Cell Therapy Programs

  • Announced updated results from the ongoing Phase 1/2 ZUMA-3 study of KTE-C19, a CD19 chimeric antigen receptor T (CAR T) cell therapy, which is investigational, for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL). With a minimum of eight weeks of follow-up, 71 percent of ALL patients (n=17/24) who received a single infusion of KTE-C19 achieved complete tumor remission (complete remission (CR) or CR with incomplete hematological recovery). The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the American Society of Hematology.
  • Announced long-term follow-up data from the ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology, and published in The New England Journal of Medicine.
  • Announced that U.S. Food and Drug Administration has granted regular approval to Yescarta, the first CAR T cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma (transformed follicular lymphoma).

Non-GAAP Financial Information

The information presented in this document has been prepared by Gilead in accordance with U.S. generally accepted accounting principles (GAAP), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. A reconciliation between GAAP and non-GAAP financial information is provided in the tables on pages 8, 9, 10 and 11.

Conference Call

At 4:30 p.m. Eastern Time today, Gilead’s management will host a conference call and a simultaneous webcast to discuss results from its fourth quarter 2017 and full year 2017 as well as provide 2018 guidance and a general business update. To access the webcast live via the internet, please connect to the company’s website at www.gilead.com/investors 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast. Alternatively, please call (877) 359-9508 (U.S.) or (224) 357-2393 (international) and dial the conference ID 6478317 to access the call.

A replay of the webcast will be archived on the company’s website for one year, and a phone replay will be available approximately two hours following the call through February 8, 2018. To access the phone replay, please call (855) 859-2056 (U.S.) or (404) 537-3406 (international) and dial the conference ID 6478317.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

Forward-looking Statements

Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include: Gilead’s ability to achieve its anticipated full year 2018 financial results; Gilead’s ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy and Vemlidy; austerity measures in European countries that may increase the amount of discount required on Gilead’s products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead’s earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada outside the United States, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead’s ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead’s earnings; Gilead’s ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead’s ability to receive regulatory approvals in a timely manner or at all, for new and current products, including BIC/FTC/TAF; Gilead’s ability to successfully commercialize its products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy and Vemlidy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead’s ability to successfully develop its hematology/oncology and inflammation/respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead’s product candidates, including GS-0976 and KTE-C19; Gilead’s ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead’s future revenues and pre-tax earnings; and other risks identified from time to time in Gilead’s reports filed with the SEC. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ significantly from these estimates. You are urged to consider statements that include the words may, will, would, could, should, might, believes, estimates, projects, potential, expects, plans, anticipates, intends, continues, forecast, designed, goal, or the negative of those words or other comparable words to be uncertain and forward-looking. Gilead directs readers to its press releases, Quarterly Report on Form 10-Q for the quarter ended September 30, 2017 and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Gilead owns or has rights to various trademarks, copyrights and trade names used in our business, including the following: GILEAD®, GILEAD SCIENCES®, AMBISOME®, AXI-CELTM, CAYSTON®, COMPLERA®, DESCOVY®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPSERA®, LETAIRIS®, ODEFSEY®, RANEXA®, SOVALDI®, STRIBILD®, TRUVADA®, TYBOST®, VEMLIDY®, VIREAD®, VOLIBRIS®, VOSEVI®, YESCARTATM and ZYDELIG®.

ATRIPLA® is a registered trademark of Gilead Sciences, LLC. LEXISCAN® is a registered trademark of Astellas U.S. LLC. MACUGEN® is a registered trademark of Eyetech, Inc. TAMIFLU® is a registered trademark of Hoffmann-La Roche Inc.

For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

 

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(unaudited)

(in millions, except per share amounts)

   
Three Months Ended Twelve Months Ended
December 31, December 31,
2017   2016 2017   2016
Revenues:
Product sales $ 5,837 $ 7,216 $ 25,662 $ 29,953
Royalty, contract and other revenues 112   104   445   437  
Total revenues 5,949   7,320   26,107   30,390  
Costs and expenses:
Cost of goods sold 1,256 1,075 4,371 4,261
Research and development expenses 1,150 1,208 3,734 5,098
Selling, general and administrative expenses 1,252   992   3,878   3,398  
Total costs and expenses 3,658   3,275   11,983   12,757  
Income from operations 2,291 4,045 14,124 17,633
Interest expense (297 ) (265 ) (1,118 ) (964 )
Other income (expense), net 132   140   523   428  
Income before provision for income taxes 2,126 3,920 13,529 17,097
Provision for income taxes 5,962   821   8,885   3,609  
Net income (loss) (3,836 ) 3,099 4,644 13,488
Net income (loss) attributable to noncontrolling interest 29   (9 ) 16   (13 )
Net income (loss) attributable to Gilead $ (3,865 ) $ 3,108   $ 4,628   $ 13,501  
 
Net income (loss) per share attributable to Gilead common stockholders - basic $ (2.96 ) $ 2.36 $ 3.54 $ 10.08
Shares used in per share calculation - basic 1,307 1,316 1,307 1,339
Net income (loss) per share attributable to Gilead common stockholders - diluted $ (2.96 ) $ 2.34 $ 3.51 $ 9.94
Shares used in per share calculation - diluted 1,307 1,327 1,319 1,358
Cash dividends declared per share $ 0.52 $ 0.47 $ 2.08 $ 1.84
 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION

(unaudited)

(in millions, except percentages and per share amounts)

   
Three Months Ended Twelve Months Ended
December 31, December 31,
2017   2016 2017   2016
Cost of goods sold reconciliation:
GAAP cost of goods sold $ 1,256 $ 1,075 $ 4,371 $ 4,261
Acquisition-related – amortization of purchased intangibles (283 ) (214 ) (912 ) (844 )
Stock-based compensation expenses(1) (12 ) (3 ) (24 ) (14 )
Other(2) 5   2   (13 ) 11  
Non-GAAP cost of goods sold $ 966   $ 860   $ 3,422   $ 3,414  
 
Product gross margin reconciliation:
GAAP product gross margin 78.5 % 85.1 % 83.0 % 85.8 %
Acquisition-related – amortization of purchased intangibles 4.8 % 3.0 % 3.6 % 2.8 %
Stock-based compensation expenses(1) 0.2 % % 0.1 % %
Other(2) (0.1 )% % 0.1 % %
Non-GAAP product gross margin(6) 83.5 % 88.1 % 86.7 % 88.6 %
 
Research and development expenses reconciliation:
GAAP research and development expenses $ 1,150 $ 1,208 $ 3,734 $ 5,098
Up-front collaboration expenses (373 )
Acquisition-related expenses – acquired IPR&D (222 ) (222 ) (400 )
Acquisition-related – IPR&D impairment (201 ) (432 )
Acquisition-related – other costs (8 ) (8 )
Stock-based compensation expenses(1) (90 ) (47 ) (232 ) (176 )
Other(2) 15   (1 ) 19   32  
Non-GAAP research and development expenses $ 845   $ 959   $ 3,291   $ 3,749  
 
Selling, general and administrative expenses reconciliation:
GAAP selling, general and administrative expenses $ 1,252 $ 992 $ 3,878 $ 3,398
Acquisition-related – transaction costs (36 ) (48 )
Acquisition-related – other costs (46 ) (46 )
Stock-based compensation expenses(1) (243 ) (52 ) (393 ) (190 )
Other(2) (4 ) (2 ) (28 ) (14 )
Non-GAAP selling, general and administrative expenses $ 923   $ 938   $ 3,363   $ 3,194  
 
Operating margin reconciliation:
GAAP operating margin 38.5 % 55.3 % 54.1 % 58.0 %
Up-front collaboration expenses % % % 1.2 %
Acquisition-related – amortization of purchased intangibles 4.8 % 2.9 % 3.5 % 2.8 %
Acquisition-related expenses – acquired IPR&D 3.7 % % 0.9 % 1.3 %
Acquisition-related – IPR&D impairment % 2.7 % % 1.4 %
Acquisition-related – transaction costs 0.6 % % 0.2 % %
Acquisition-related – other costs 0.9 % % 0.2 % %
Stock-based compensation expenses(1) 5.8 % 1.4 % 2.5 % 1.3 %
Other(2) (0.3 )% % 0.1 % (0.1 )%
Non-GAAP operating margin(6) 54.0 % 62.3 % 61.4 % 65.9 %
 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)

(unaudited)

(in millions, except percentages and per share amounts)

   
Three Months Ended Twelve Months Ended
December 31, December 31,
2017   2016 2017   2016
Interest expense reconciliation:
GAAP interest expense $ (297 ) $ (265 ) $ (1,118 ) $ (964 )
Acquisition-related – transaction costs     18    
Non-GAAP interest expense $ (297 ) $ (265 ) $ (1,100 ) $ (964 )
 
Effective tax rate reconciliation:
GAAP effective tax rate 280.5 % 20.9 % 65.7 % 21.1 %
Up-front collaboration expenses % % % (0.4 )%
Acquisition-related – amortization of purchased intangibles (1.1 )% (1.5 )% (1.2 )% (0.8 )%
Acquisition-related expenses – acquired IPR&D (2.1 )% % (0.4 )% (0.4 )%
Acquisition-related – transaction costs 0.2 % % % %
Acquisition-related – other costs 0.3 % % % %
Stock-based compensation expenses(1)(3) 2.6 % % 0.8 % %
Tax Reform impact(5) (258.3 )% % (40.6 )% %
Other(2) 0.2 % % % %
Non-GAAP effective tax rate(6) 22.2 % 19.4 % 24.5 % 19.5 %
 
Net income (loss) attributable to Gilead reconciliation:
GAAP net income (loss) attributable to Gilead $ (3,865 ) $ 3,108 $ 4,628 $ 13,501
Up-front collaboration expenses 373
Acquisition-related – amortization of purchased intangibles 246 206 851 818
Acquisition-related expenses – acquired IPR&D 222 222 400
Acquisition-related – IPR&D impairment 198 371
Acquisition-related – transaction costs 24 48
Acquisition-related – other costs 36 36
Stock-based compensation expenses(1)(3) 208 73 369 276
Tax Reform impact(5) 5,490 5,490
Other(2) (18 )   10   (26 )
Non-GAAP net income attributable to Gilead $ 2,343   $ 3,585   $ 11,654   $ 15,713  
 
Diluted earnings / (loss) per share reconciliation:
GAAP diluted earnings / (loss) per share(4) $ (2.96 ) $ 2.34 $ 3.51 $ 9.94
Up-front collaboration expenses 0.27
Acquisition-related – amortization of purchased intangibles 0.19 0.16 0.65 0.60
Acquisition-related expenses – acquired IPR&D 0.17 0.17 0.29
Acquisition-related – IPR&D impairment 0.15 0.27
Acquisition-related – transaction costs 0.02 0.04
Acquisition-related – other costs 0.03 0.03
Stock-based compensation expenses(1)(3) 0.16 0.06 0.28 0.20
Tax Reform impact(5) 4.16 4.16
Other(2) (0.01 )   0.01   (0.02 )
Non-GAAP diluted earnings per share(6) $ 1.78   $ 2.70   $ 8.84   $ 11.57  
 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)

(unaudited)

(in millions, except percentages and per share amounts)

 
  Three Months Ended   Twelve Months Ended
December 31, December 31,
2017   2016 2017   2016
Non-GAAP adjustment summary:
Cost of goods sold adjustments $ 290 $ 215 $ 949 $ 847
Research and development expenses adjustments 305 249 443 1,349
Selling, general and administrative expenses adjustments 329 54 515 204
Interest expense adjustments     18    
Total non-GAAP adjustments before tax 924 518 1,925 2,400
Income tax effect(3) (206 ) (40 ) (389 ) (191 )
Tax Reform impact(5) 5,490 5,490
Other(2)   (1 )   3  
Total non-GAAP adjustments after tax $ 6,208   $ 477   $ 7,026   $ 2,212  
Notes:
(1)   Stock-based compensation expenses for the three and twelve months ended December 31, 2017 include $238 million associated with Gilead’s acquisition of Kite
(2) Amounts related to restructuring, contingent consideration, consolidation of a contract manufacturer and/or other individually insignificant amounts
(3) Income tax effect related to stock-based compensation expenses for the three and twelve months ended December 31, 2017 includes the incremental tax benefit of $31 million and $91 million, respectively, recognized from the adoption of Accounting Standards Update 2016-09 “Improvements to Employee Share-Based Payment Accounting”
(4) Shares used in loss per share calculation for the three months ended December 31, 2017 exclude 13 million shares from dilutive equity awards
(5) Amounts for the three and twelve months ended December 31, 2017 include an estimated charge of $5.8 billion relating to the deemed repatriation of unremitted earnings of foreign subsidiaries and an estimated benefit of $308 million relating to the re-measurement of deferred taxes
(6) Amounts may not sum due to rounding
 

GILEAD SCIENCES, INC.

RECONCILIATION OF GAAP TO NON-GAAP 2018 FULL YEAR GUIDANCE

(unaudited)

(in millions, except percentages and per share amounts)

 

Provided
February 6, 2018

Projected product gross margin GAAP to non-GAAP reconciliation:
GAAP projected product gross margin 78% - 80%
Acquisition-related expenses 7% - 7%
Non-GAAP projected product gross margin(1) 85% - 87%
 
Projected research and development expenses GAAP to non-GAAP reconciliation:
GAAP projected research and development expenses $3,785 - $4,050
Stock-based compensation expenses(2) (315) - (350)
Acquisition-related expenses / up-front collaboration expenses (70) - (100)
Non-GAAP projected research and development expenses $3,400 - $3,600
 
Projected selling, general and administrative expenses GAAP to non-GAAP reconciliation:
GAAP projected selling, general and administrative expenses $3,865 - $4,110
Stock-based compensation expenses(2) (425) - (450)
Acquisition-related – other costs (40) - (60)
Non-GAAP projected selling, general and administrative expenses $3,400 - $3,600
 
Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses (3) :
Acquisition-related expenses / up-front collaboration expenses $0.91 - $0.95
Stock-based compensation expenses(2) 0.50 - 0.56
Projected diluted EPS impact of acquisition-related, up-front collaboration, stock-based compensation and other expenses(3) $1.41 - $1.51
 
Notes:
(1) Stock-based compensation expenses have a less than one percent impact on non-GAAP projected product gross margin
(2) Includes stock-based compensation expenses associated with Gilead’s acquisition of Kite
(3) Excludes changes to our estimates relating to Tax Reform during 2018. As a result, we are unable to project an effective tax rate on a GAAP basis
 

GILEAD SCIENCES, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(unaudited)

(in millions)

   
December 31, December 31,
2017 2016 (1)
 
Cash, cash equivalents and marketable securities $ 36,694 $ 32,380
Accounts receivable, net 3,851 4,514
Inventories 801 1,587
Property, plant and equipment, net 3,295 2,865
Intangible assets, net 17,100 8,971
Goodwill 4,159 1,172
Other assets 4,383   5,488
Total assets $ 70,283   $ 56,977
 
Current liabilities $ 11,635 $ 9,218
Long-term liabilities 38,147 28,396
Stockholders’ equity(2) 20,501   19,363
Total liabilities and stockholders’ equity $ 70,283   $ 56,977

 

Notes:
(1)   Derived from the audited consolidated financial statements as of December 31, 2016. Certain amounts have been reclassified to conform to current year presentation
(2) As of December 31, 2017, there were 1,308 million shares of common stock issued and outstanding
 

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY

(unaudited)

(in millions)

   
Three Months Ended Twelve Months Ended
December 31, December 31,
2017   2016 2017   2016
Antiviral products:
Genvoya – U.S. $ 844 $ 485 $ 3,033 $ 1,301
Genvoya – Europe 176 68 534 160
Genvoya – Other International 40   10   107   23
1,060   563   3,674   1,484
 
Truvada – U.S. 631 604 2,266 2,384
Truvada – Europe 117 200 644 913
Truvada – Other International 49   64   224   269
797   868   3,134   3,566
 
Harvoni – U.S. 425 976 3,053 4,941
Harvoni – Europe 121 363 704 1,810
Harvoni – Other International 98   301   613   2,330
644   1,640   4,370   9,081
 
Epclusa – U.S. 262 934 2,404 1,591
Epclusa – Europe 220 101 869 141
Epclusa – Other International 83   13   237   20
565   1,048   3,510   1,752
 
Atripla – U.S. 314 444 1,288 1,898
Atripla – Europe 76 108 335 520
Atripla – Other International 50   55   183   187
440   607   1,806   2,605
 
Descovy – U.S. 276 112 958 226
Descovy – Europe 77 34 226 69
Descovy – Other International 12   3   34   3
365   149   1,218   298
 
Odefsey – U.S. 276 138 964 302
Odefsey – Europe 45 17 132 27
Odefsey – Other International 4     10  
325   155   1,106   329
 
Stribild – U.S. 179 296 811 1,523
Stribild – Europe 34 71 195 314
Stribild – Other International 9   20   47   77
222   387   1,053   1,914
 
Complera / Eviplera – U.S. 91 146 406 821
Complera / Eviplera – Europe 118 135 503 580
Complera / Eviplera – Other International 13   16   57   56
222   297   966   1,457
 
Viread – U.S. 119 171 514 591
Viread – Europe 36 68 238 302
Viread – Other International 57   85   294   293
212   324   1,046   1,186
 
Vosevi – U.S. 150 267
Vosevi – Europe 17 22
Vosevi – Other International 3     4  
170     293  
 

GILEAD SCIENCES, INC.

PRODUCT SALES SUMMARY - (Continued)

(unaudited)

(in millions)

   
Three Months Ended Twelve Months Ended
December 31, December 31,
2017   2016 2017   2016
Sovaldi – U.S. $ 10 $ 112 $ 130 $ 1,895
Sovaldi – Europe 20 164 258 891
Sovaldi – Other International 87   265   576   1,215
117   541   964   4,001
 
Other Antiviral – U.S. 56 12 157 48
Other Antiviral – Europe 7 4 24 22
Other Antiviral – Other International 11     15   2
74   16   196   72
 
Total antiviral products – U.S. 3,633 4,430 16,251 17,521
Total antiviral products – Europe 1,064 1,333 4,684 5,749
Total antiviral products – Other International 516   832   2,401   4,475
5,213   6,595   23,336   27,745
 
Other products:
Letairis 233 226 887 819
Ranexa 200 210 717 677
AmBisome 90 94 366 356
Zydelig 39 39 149 168
Other 62   52   207   188
624   621   2,326   2,208
 
Total product sales $ 5,837   $ 7,216   $ 25,662   $ 29,953

Contact information

Gilead Sciences, Inc.
Investors
Robin Washington, 650-522-5688
Sung Lee, 650-524-7792
Media
Amy Flood, 650-522-5643

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis21.2.2018 21:01Pressemelding

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it is initiating the first Phase 3 study of VX-659, tezacaftor and ivacaftor as an investigational triple combination regimen for people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation. The study will enroll 360 patients, and the primary endpoint of the study is the mean absolute change from baseline in percent predicted forced expiratory volume in one second (ppFEV1) at week four of treatment. The study is designed to support the submission of a New Drug Application (NDA) in the U.S. using data from the 4-week primary efficacy endpoint together with safety data through 12 weeks of treatment. “Our goal is to bring the best triple combination to patients as rapidly as possible, and this first Phase 3 study of VX-659 in combination with tezacaftor and ivacaftor is a significant step toward that goal,” said Jeffrey Chodakewitz, M.D., Executive Vice President and Chief Medical

Universal Laser Systems® Expands Portfolio of Laser Material Processing Systems with the ULTRA Platform Series21.2.2018 18:00Pressemelding

ULTRA platform-based laser systems are designed and ideally suited for precision laser cutting, laser ablation, and laser surface modification in manufacturing, research and development, academic research and prototyping environments. Major features of the series include rapid, high-accuracy laser beam positioning, and the flexibility to be configured with 9.3 and 10.6 µm CO2 lasers and 1.06 µm fiber lasers. All lasers are air-cooled in a range of power from 10 to 150 watts for CO2 and 40 to 50 watts for fiber lasers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005364/en/ The ULTRA 9MW offers MultiWave processing of thin materials. (Photo: Business Wire) The variety of wavelengths and power ranges make the ULTRA platforms highly effective in the areas of organic material modification, including plastic films, industrial fabrics, engineering plastics, laminating adhesives, composite materials, and many others utilized

Luxoft One of Six Companies Collaborating with Amazon Web Services to Accelerate Blockchain Adoption21.2.2018 16:30Pressemelding

Luxoft Holding Inc (NYSE:LXFT), a global IT service provider, announces today that it is collaborating with Amazon Web Services (AWS) to enable corporates to adopt blockchain and Distributed Ledger Technologies (DLT). Luxoft is one of six IT and consulting services companies to make its blockchain advisory and development services available to AWS users. “We are very excited to be working with AWS to help users engage with blockchain and DLTs,” said Vasiliy Suvorov, Vice President of Technology Strategy at Luxoft. “Blockchain is about removing data silos, improving trust and operational efficiencies. By using AWS to deploy and integrate DLTs into day-to-day processes, businesses can revolutionize how they operate.” Luxoft helps accelerate the deployment and integration of blockchain and DLT-based projects on AWS and is already working on a number of DLT projects using the cloud. For example, Luxoft is building a healthcare claims processing system for a leading healthcare provider usin

Westinghouse Electric Company to Provide Engineering Support at Vandellós 1 in Partnership with EDF21.2.2018 16:30Pressemelding

Westinghouse Electric Company and Electricité de France (EDF), in partnership, announced today that they have been awarded a contract from Empresa Nacional de Residuos Radiactivos (ENRESA), the Spanish agency responsible for radioactive waste management and nuclear plant decommissioning. The agreement covers a four-year engineering support contract for the latency phase of the dismantling and decommissioning project at Vandellós I Nuclear Power Station in Spain and includes the preparation of technical and licensing documentation. “We are extremely pleased that ENRESA has selected Westinghouse and EDF to continue supporting the decommissioning activities at Vandellós I Nuclear Power Station,” said Yves Brachet, Westinghouse vice president, Global Decommissioning, Decontamination, Remediation and Waste Management. “This contract further demonstrates Westinghouse’s global capabilities and expertise in providing innovative decommissioning solutions.” Sylvain Granger, head of EDF's decommi

H.I.G. Europe Completes a Strategic Investment in Puerto de Indias Group21.2.2018 14:02Pressemelding

H.I.G. Capital (“H.I.G.”), a leading global private equity investment firm with more than €20 billion of equity capital under management, announced that one of its affiliates has acquired a majority interest in Puerto de Indias Group (“Puerto de Indias” or the “Company”), with the goal of accelerating the Company’s growth initiatives and supporting its expansion into international markets. Headquartered in Seville, Spain, Puerto de Indias was founded by Jose Antonio and Francisco Rodriguez Fernandez, and has become in a short period of time the leading player in the Rosé Gin market in Spain. Puerto de Indias has in place an ambitious international expansion plan targeting the development of a commercial network in Europe, the U.S., and Latin America, as well as strategic alliances with strong international distributors. Leopoldo Reaño, Principal at H.I.G. Europe, commented on the transaction: “We are thrilled to have the opportunity to support the management team led by Jose Antonio an

Savi Adds Supply Chain Star Johannes Giloth to Advisory Board21.2.2018 13:02Pressemelding

Savi®, an innovator in big data/machine learning analytic solutions, supply chain management software, and sensor technology, today announced that Johannes Giloth has joined its board of advisers. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180221005117/en/ Johannes Giloth (Photo: Business Wire) Giloth is a long-time leader in procurement, supply chain and manufacturing. He currently serves as Chief Procurement Officer and Senior Vice President of Operations at Nokia where he is in charge of every aspect of operations accountability worldwide — from demand planning to execution, procurement to manufacturing. “Johannes understands the impact the explosion of data will have on the supply chain. And his tremendous success as an innovative supply chain leader proves he knows what companies need to transform their supply chains,” said Rich Carlson, CEO of Savi Technology. “I’m thrilled to have him join Savi’s advisory board. As